- Patent issuance adds to SNIPR’s extensive intellectual property portfolio, comprising more than 60 granted worldwide patents, including in the USA and Europe
- Patent covers the use of killing of bacteria at least 1000-fold in a microbiome using any CRISPR/Cas system
- USPTO has also issued a Notice of Allowance for methods of using CRISPR lytic phage
Copenhagen, December 22 2022: SNIPR Biome ApS (“SNIPR” or “the Company”), the company pioneering CRISPR-based microbial gene therapy, announces today the grant of a new patent by the US Patent and Trademark Office (USPTO). This patent represents a further addition to the Company’s extensive intellectual property portfolio, comprising more than 60 granted patents worldwide covering SNIPR’s technology platform, which enables editing of prokaryotes using CRISPR/Cas.
The USPTO has granted patent number US11,517,582, which covers the use of CRISPR/Cas systems to achieve selective killing of bacteria by at least 1000-fold in situations where bacteria are growing in a mixed population. This patent covers the use of any type of CRISPR/Cas.
In natural environments, such as in gut microbiomes, bacteria are found growing in mixed populations and it has been difficult to selectively target individual bacterial species with conventional broad-spectrum antibiotics. SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease, such as an infection.
SNIPR has also received an allowance by the USPTO indicating that it will shortly grant a US patent broadly covering methods of using CRISPR lytic phage, by use of any CRISPR/Cas system and for any application (US 15/817,144). This expands the Company’s portfolio protecting CRISPR lytic phage. In August 2022, SNIPR was awarded patent number US11,400,110 which covers lytic phage armed with CRISPR gene editing systems. CRISPR and phage lysis of target bacteria is a potent combination for therapeutics, with potential for broad application, including the targeting of any bacteria for any medical use.
Dr Christian Grøndahl, Co-founder and CEO of SNIPR Biome, commented: “This expansion of our patent estate strengthens our already extensive intellectual property portfolio covering the use of CRISPR/Cas to edit prokaryotes. SNIPR Biome has exclusive, worldwide rights to this patent estate for medical applications, which supports our pipeline and lead program SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients. We will continue our pioneering work in this field as we advance our mission of developing CRISPR-based medicines for the benefit of patients suffering from life-threatening diseases.”
Earlier this year, the Company made its IP available for academic and non-profit research use without a written license. Parties interested in licensing SNIPR’s intellectual property should contact the Company at firstname.lastname@example.org.